INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 47m ago
HOUSE PTR6m ago
SEC 13F6m ago
ROBINHOOD CHAIN6m ago
SEC FORM 4/Derivative conversionVerified data

Li Yishan reported BLSM

Director, Executive Chairman, 10% Owner · BlossomHill Therapeutics, Inc. · Common Stock

Side
C
Value
—
Shares
124.8K
Price
—
Executed
Aug 10, 2026
Disclosed
Aug 10, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Aug 10 executedAug 10, 2026 disclosed

BLSM · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Derivative conversion — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BLSM

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    LP
    Liptak Vincent PaulGeneral Counsel
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    22.7K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    34
    LP
    Liptak Vincent PaulGeneral Counsel
    BLSMBlossomHill Therapeutics, Inc.
    Open-market purchase
    		BUY$40K
    2,500 sh
    		Aug 7, 2026Aug 10, 2026
    traded Aug 7, 2026
    		+3dSEC FORM 4

    Evidence

    13
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    113.4K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    30
    LP
    Liptak Vincent PaulGeneral Counsel
    BLSMBlossomHill Therapeutics, Inc.
    Open-market purchase
    		BUY$35K
    2,200 sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    AS
    Agrawal SundeepDirector
    BLSMBlossomHill Therapeutics, Inc.
    Grant or award
    		A—
    23.9K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agrawal SundeepDirector
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    578.5K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    1.60M sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    124.8K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Grant or award
    		A—
    676.2K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    1.60M sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    113.4K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    124.8K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    KA
    Keyes Jason AChief Financial Officer
    BLSMBlossomHill Therapeutics, Inc.
    Grant or award
    		A—
    56.7K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OR
    Oxnard Geoffrey RaymondChief Medical Officer
    BLSMBlossomHill Therapeutics, Inc.
    Grant or award
    		A—
    61.8K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agrawal SundeepDirector
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    578.5K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    LY
    Li YishanDirector, Executive Chairman, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    1.60M sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    13
    LY
    Li YishanDirector, Executive Chairman, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    113.4K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    LY
    Li YishanDirector, Executive Chairman, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Grant or award
    		A—
    112.7K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    LY
    Li YishanDirector, Executive Chairman, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    1.60M sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    LY
    Li YishanDirector, Executive Chairman, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    113.4K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001772233-26-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 10, 2026
    Published
    Aug 10, 2026
    Ingested by INSIDER
    Nov 5, 02:24 UTC
    Last re-read
    Nov 5, 02:24 UTC

    Extracted facts

    Filer
    Li Yishan
    Role
    Director, Executive Chairman, 10% Owner
    Transaction
    Derivative conversionAs filed: “C”
    Asset
    BlossomHill Therapeutics, Inc.
    Ticker
    BLSM
    Shares
    124.8K
    Execution date (reported)
    Aug 10, 2026
    Owned after transaction
    124.8K shares
    Days from execution to publication
    0

    What this establishes

    Li Yishan filed this Form 4 reporting a derivative conversion of BLSM on Aug 10, 2026. It became public on Aug 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Executive Chairman, 10% Owner
    Li Yishancik:0001772233
    Issuer
    BlossomHill Therapeutics, Inc.cik:0001839970

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.